StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) bonds

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$2.15B
$208.97M due within a year
Net debt
$1.98B
After $163.14M of cash
Implied interest rate
0.99%
FY2025 interest ÷ average debt
Interest coverage
25.9×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Halozyme Therapeutics's 10-Q for the period ended Jun 30, 2026

Coupon by maturity

Each circle is a note, sized by the amount issued. The line is what the US Treasury pays today for the same time to maturity.

IssueCouponMaturesAmount issuedCarrying value
2027 Convertible Notes
Convertible at $77 a share
0.25%2027$209.58M$208.97M
Convertible Senior Notes due 2027
Convertible at $77 a share
0.25%2027$805.00M–
2028 Convertible Notes
Convertible at $56 a share
1.00%2028$720.00M$464.44M
Convertible Senior Notes due 2028
Convertible at $56 a share
1.00%2028$470.00M$465.48M
2031 Convertible Notes
Convertible at $87 a share
0.00%2031$750.00M$736.35M
2032 Convertible Notes
Convertible at $87 a share
0.88%2032$750.00M$735.85M
2024 Convertible Notes
Convertible at $24 a share
1.25%–$460.00M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Credit Agreement$750.00M

See a number that looks wrong?